The biotechnology market is expected to soar past $950B US by 2027, fueled by the need for solutions to chronic disease, the rapid development of bioengineering tools, and an intense interest in addressing the diseases of aging. Despite this, some are calling this present time a biotechnology winter, with many companies trading for less than cash and widespread reports of slowdown in investment in the sector are affecting companies across the full spectrum of development. We have gathered a stellar panel across multiple perspectives in the industry to discuss what is exciting on the horizon, perspectives on the investment landscape, and what promising technologies are emerging.
Light Refreshments will be served.
- Elizabeth Ng, CEO, Ocean Biomedical (Nasdaq: OCEA)
- Eddie Eltoukhy, Pear VC
- Keith Koo, Host Silicon Valley Insider, GP
- Michael King, Managing Director and Head of Healthcare Research at EF Hutton
- Niki Santo, Co-Founder/CEO, Swaza
Because this event is in person, you acknowledge the below by coming to this event.
I acknowledge and understand that: (i) I am not required to participate in this event; (ii) my participation is voluntary and at my sole risk; and (iii) I am responsible for my own protection against Covid-19, including, without limitation, following all health and safety protocols communicated to me or posted at the event venue.
Please make sure you are a current member of our club before registering. If you are unsure please ask email@example.com or if you would like to join MIT Club of Northern California, click here.